Abstract
ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Current Bioactive Compounds
Title: AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Volume: 7 Issue: 1
Author(s): David P. Nowotnik
Affiliation:
Keywords: HPMA polymer, DACH platinum, AP5346, ProLindac, recurrent ovarian cancer, tumor targeting, clinical trials, chemotherapeutic agents, anticancer, third generation polymer platinum prodrug
Abstract: ProLindac™ (AP5346) is a 25 kDa polymer delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to which DACH (diaminocyclohexane) platinum is bound. DACH platinum is the active moiety in the approved chemotherapeutic, oxaliplatin. The AP5346 polymer prodrug is currently in phase II clinical development. The polymer targets the drug to tumors and a pH-sensitive linker releases platinum more rapidly in low pH environments, as found typically in many tumors. ProLindac has completed a Phase I study in solid tumor cancer patients and has recently completed a Phase I/II monotherapy study in patients with recurrent ovarian cancer. With promising efficacy and safety data from these studies, clinical studies of ProLindac used in combination with other chemotherapeutic agents, including paclitaxel, are planned.
Export Options
About this article
Cite this article as:
P. Nowotnik David, AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163794
DOI https://dx.doi.org/10.2174/157340711795163794 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Editorial (Thematic Issue: New Trends in Pharmaceutical Nanotechnology)
Current Pharmaceutical Design Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry MicroRNA in Aging: From Discovery to Biology
Current Genomics The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration
Current Drug Targets RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Current Development of Metal Complexes with Diamine Ligands as Potential Anticancer Agents
Current Medicinal Chemistry Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Anti-Cancer Agents in Medicinal Chemistry